Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and challenges shaping SMMT's future.

Including today's surge, Summit shares have risen more than 35% this year. U.S.-listed shares of AstraZeneca, which fell 2.5% in recent trading to pace Nasdaq decliners Thursday, are up about 6% ...

AstraZeneca is in talks with Summit Therapeutics over a potential licensing deal for the U.S. biotech’s ivonescimab, Bloomberg reported Thursday, citing people familiar with the matter.

Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ: AZN) is in discussions ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing ...

Investing.com -- Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a ...

All told, a deal between the two companies could pay out as much as $15 billion. Both Summit and AstraZeneca declined comment on the Bloomberg article.

Shares of Summit Therapeutics surged 9.7% to $25.81 in morning trade. The Menlo Park, California-based drug developer did not immediately respond to Reuters' request seeking comment, while an ...

Investing.com -- Summit Therapeutics (NASDAQ: SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ: AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a ...

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...